Search Results for:
-
S-TARget Seeking $8M for Allergy Vaccine Platform
It already has completed a preclinical study in healthy rhesus monkeys and obtained preclinical proof of concept in the form of a favorable cytokine profileBy Cormac Sheridan | BioWorld Today | Wednesday, April 10, 2013 -
S-TARget Seeking $8M for Allergy Vaccine Platform
It already has completed a preclinical study in healthy rhesus monkeys and obtained preclinical proof of concept in the form of a favorable cytokine profileBy Cormac Sheridan | BioWorld International | Wednesday, April 10, 2013 -
Other News To Note
S-TARget Therapeutics, of Vienna, Austria, said it achieved in vivo proof of concept for drug candidate SG100, which is in development for the prevention and therapy of severe allergic asthma caused by house dust mite (HDM) allergensBioWorld Today | Tuesday, April 9, 2013 -
Milestone Payments From Corporate Partners: March 2013
Ltd. (Osaka, Japan) ND For successfully determining a novel protein crystal structure of an undisclosed proprietary G-protein-coupled receptor drug discovery target 3/8/13 ThromboGenics NV (Leuven, Belgium) Alcon Inc. (unit of Novartis AG; Basel, Switzerland) €45 ($58.8) For formal European Union approval for Jetrea for treating patients with vitreomacular traction 3/18/13 Tris Pharma Inc. (Monmouth Junction, N.J.) Vernalis plc (Winnersh, UK) ND For its achievement of proof of concept for theBioWorld Insight | Monday, April 8, 2013 -
IPO Flurry Continues: Receptos Files Proposed $86M Offering
Last month, it inked a deal with AbbVie, of Chicago, giving the big pharma firm an option to RPC4046 following the Phase II proof-of-concept trial in EoEBy Jennifer Boggs | BioWorld Today | Monday, April 8, 2013 -
Bench Press: BioWorld Looks at Translational Medicine
Inhibitor Works, but Not as Suspected A team from Agios Pharmaceuticals Inc., along with academic and industrial collaborators, published proof-of-concept data that inhibiting the metabolic enzymes IDH-1 and IDH-2 can lead stem-like leukemia and brain tumor cells to differentiate into mature cells, which in turn stops them from continuing to divideBioWorld Today | Monday, April 8, 2013 -
Topical HDAC Inhibitor Could 'Shape' CTCL Care
Earlier this year, Shape completed a proof-of-concept Phase Ib study of SHP-141 in psoriasis...The strategy is to generate clinical proof of concept with the molecule, then sell the company to a larger pharmaceutical company that can do the late-stage development and commercialization," Onsi said, adding that Healthcare Ventures plans to remain the sole venture partnerBy Marie Powers | BioWorld Today | Friday, April 5, 2013 -
Themis Plans Trials for Dengue and Chikungunya Vaccines
But over this year and next, its main priority will be to obtain clinical proof of concept for its two lead programs, as well scaling up manufacturing and identifying the appropriate regulatory pathways.By Cormac Sheridan | BioWorld International | Wednesday, April 3, 2013 -
Other News To Note
Galapagos said it intends to start a proof-of-concept study in ulcerative colitis patients in the second quarterBioWorld International | Wednesday, April 3, 2013 -
Themis Plans Trials for Dengue And Chikungunya Vaccines
But over this year and next, its main priority will be to obtain clinical proof of concept for its two lead programs, as well scaling up manufacturing and identifying the appropriate regulatory pathways.By Cormac Sheridan | BioWorld Today | Monday, April 1, 2013 -
Edison Pharma Lands Dainippon in Potential $545M Japan Deal
Founded in late 2005, Edison worked quietly for six years to demonstrate proof of concept on its translational platform, based on redox biochemistry – the foundation from which cells generate and regulate energy metabolism – and to bridge key discoveries in genetically confirmed pediatric rare mitochondrial diseases to major adult central nervous system disorders such as Alzheimer's disease and Parkinson's disease, where redox and mitochondrial dysfunction also may play a critical roleBy Marie Powers | BioWorld Today | Friday, March 29, 2013 -
Clinic Roundup
Galapagos said it intends to start a proof-of-concept study in ulcerative colitis patients in the second quarterBioWorld Today | Thursday, March 28, 2013 -
Other News To Note
3SBio Inc., of Shenyang, China, called an extraordinary general meeting of shareholders for April 25 to vote on the merger plan with Decade Sunshine Ltd. and its wholly owned subsidiary Decade Sunshine Merger Sub. The merger would result in 3SBio becoming a privately held subsidiary of Decade Sunshine Ltd., with its American Depository Shares no longer listed on the Nasdaq Global Market. The company's board of directors approved the merger agreement and recommended that shareholders vote toBioWorld International | Wednesday, March 27, 2013 -
Third Rock Raises $516M, Seeks Early Stage Firms
Kala just completed a Series A for $11.5 million through a consortium including Crown Venture Fund LLC, Lux Capital Management and Polaris Venture Partners in addition to Third Rock Ventures to advance its ophthalmic programs through clinical proof of conceptBy Catherine Shaffer | BioWorld Today | Tuesday, March 26, 2013 -
Collaborations Between Biotechnology Companies And Government/Nonprofit Institutions: Dec. 1, 2012 - March 21, 2013
proof-of-concept trials 12/14/12 Genisphere Inc. (Hatfield, Pa.) Lankenau Institute for Medical Research Partnership To develop nanotherapeutic products for cancers and eye diseases The two organizations have an existing collaboration in the area of inflammatory bowel disease biomarkers centered on Genisphere's 3DNA dendrimer technology for delivery of a variety of therapeutic agents to cells 12/4/12 Gentium SpA (Villa Guardia, Italy) National University Corporation Hamamatsu University SchoolBioWorld Insight | Monday, March 25, 2013 -
Clinic Roundup
Summit plc, of Oxford, UK, said it plans to initiate a two-part proof-of-concept trial with lead candidate SMT-C1100 in Duchenne's muscular dystrophy (DMDBioWorld Today | Friday, March 22, 2013 -
Bluebird Bio, Celgene Hatch Gene Therapy Collaboration
Until 2010, Genetix's key accomplishment was human proof-of-concept data for programs in CCALD and thalassemiaBy Marie Powers | BioWorld Today | Friday, March 22, 2013 -
Clinic Roundup
Soricimed Biopharma Inc., of Toronto, reported results from molecular imaging investigation that provided proof of concept for the use of SOR peptides to detect and potentially treat ovarian, breast, thyroid, prostate and colon cancerBioWorld Today | Wednesday, March 20, 2013 -
Other News To Note
GeNeuro is planning a proof-of-concept study after completion of an extension trial in early 2014BioWorld International | Wednesday, March 20, 2013 -
Helmedix Lands Seed Funding to Back Helminth Peptide R&D
We will keep options open, but would like to get to clinical proof of concept in humans if we can."By Nuala Moran | BioWorld International | Wednesday, March 20, 2013
Category
Current Filters
- xproof of concept
Related Keywords
Categories
- x BioWorld Today (1423)
- x BioWorld International (481)
- x BioWorld Insight (188)
- x Bio Perspectives (72)
- x State of the Industry Report (24)
- x BioWorld Snapshots (15)
- x Biotech Innovations (13)
- x Top 25 Drug Report (4)
- x BioWorld Genomics Review (2)
- x Market-Leading Biotech Drugs (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.